Annexon マネジメント

マネジメント基準チェック /44

Annexonの CEO はDoug Loveで、 Dec2014年に任命され、の在任期間は 9.92年です。の年間総報酬は$ 2.45Mで、 24.2%給与と75.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.28%を直接所有しており、その価値は$ 1.53M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と6.1年です。

主要情報

Doug Love

最高経営責任者

US$2.5m

報酬総額

CEO給与比率	24.2%
CEO在任期間	9.9yrs
CEOの所有権	0.3%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	6.1yrs

経営陣の近況

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

CEO報酬分析

Annexon の収益と比較して、Doug Love の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$118m
Jun 30 2024	n/a	n/a	-US$115m
Mar 31 2024	n/a	n/a	-US$121m
Dec 31 2023	US$2m	US$593k	-US$134m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$145m
Dec 31 2022	US$4m	US$569k	-US$142m
Sep 30 2022	n/a	n/a	-US$145m
Jun 30 2022	n/a	n/a	-US$145m
Mar 31 2022	n/a	n/a	-US$140m
Dec 31 2021	US$8m	US$534k	-US$130m
Sep 30 2021	n/a	n/a	-US$116m
Jun 30 2021	n/a	n/a	-US$103m
Mar 31 2021	n/a	n/a	-US$84m
Dec 31 2020	US$5m	US$446k	-US$70m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$3m	US$396k	-US$38m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$518k	US$379k	-US$18m

報酬と市場: Dougの総報酬 ($USD 2.45M ) は、 US市場 ($USD 2.14M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Dougの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Doug Love (56 yo)

9.9yrs

在職期間

US$2,453,184

報酬

Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Douglas Love	CEO, President & Director	9.9yrs	US$2.45m	0.28% $ 1.5m
Dean Artis	Chief Scientific Officer & Executive VP	1.8yrs	US$1.83m	0.047% $ 258.7k
Ted Yednock	Executive VP	3.1yrs	US$1.14m	0.067% $ 366.8k
Jennifer Lew	Executive VP	5.4yrs	US$1.44m	0.026% $ 141.5k
Michael Overdorf	Executive VP & Chief Business Officer	4.3yrs	US$1.40m	0.033% $ 183.4k
Henk-Andre Kroon	Senior Vice President of Translational Medicine	no data	データなし	データなし
Jamie Dananberg	Executive VP & Chief Medical Officer	1.3yrs	データなし	データなし
Shikhar Agarwal	Senior VP & Head of Commercial	less than a year	データなし	データなし
Sunil Mehta	Senior VP of Medical Affairs	less than a year	データなし	データなし

2.5yrs

平均在職期間

59.5yo

平均年齢

経験豊富な経営陣: ANNXの経営陣は経験豊富であると考えられます ( 2.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Douglas Love	CEO, President & Director	9.9yrs	US$2.45m	0.28% $ 1.5m
Ted Yednock	Executive VP	less than a year	US$1.14m	0.067% $ 366.8k
Muneer Satter	Independent Director	9.9yrs	US$103.93k	0.76% $ 4.1m
Thomas Wiggans	Independent Chairman	7.8yrs	US$132.43k	0.00025% $ 1.4k
Jung Choi	Independent Director	4.4yrs	US$100.93k	0% $ 0
William Waddill	Independent Director	3.3yrs	US$103.43k	0% $ 0
Thomas Maniatis	Member of Scientific Advisory Board	no data	データなし	データなし
David Holtzman	Member of Scientific Advisory Board	no data	データなし	データなし
Stephen Hauser	Member of Scientific Advisory Board	no data	データなし	データなし
Jeffrey Goldberg	Member of Scientific Advisory Board	no data	データなし	データなし
P. Willison	Member of Scientific Advisory Board	no data	データなし	データなし
Beth Stevens	Member of Scientific Advisory Board	no data	データなし	データなし

6.1yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: ANNXの取締役会は経験豊富であると考えられます ( 6.1年の平均在任期間)。

Annexon マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

CEO, President & Director exercised options to buy US$833k worth of stock.

Annexon, Inc. Announces Management Appointments

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Executive VP notifies of intention to sell stock

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Annexon, Inc. Announces Executive Changes

Recent updates

CEO, President & Director exercised options to buy US$833k worth of stock.

Annexon, Inc. to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Annexon, Inc. Announces Management Appointments

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon, Inc. Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Annexon, Inc. Announces Executive Changes

Independent Director has left the company

マネジメント基準チェック /44